DK3133396T3 - METHODS OF TREATMENT WHEN USING AMMONIA-CLEANING MEDICINES - Google Patents

METHODS OF TREATMENT WHEN USING AMMONIA-CLEANING MEDICINES Download PDF

Info

Publication number
DK3133396T3
DK3133396T3 DK16176456.8T DK16176456T DK3133396T3 DK 3133396 T3 DK3133396 T3 DK 3133396T3 DK 16176456 T DK16176456 T DK 16176456T DK 3133396 T3 DK3133396 T3 DK 3133396T3
Authority
DK
Denmark
Prior art keywords
hpn
pba
patient
pagn
ammonia
Prior art date
Application number
DK16176456.8T
Other languages
Danish (da)
English (en)
Inventor
Bruce Scharschmidt
Original Assignee
Horizon Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Llc filed Critical Horizon Therapeutics Llc
Priority claimed from EP09739263.3A external-priority patent/EP2330892B1/en
Application granted granted Critical
Publication of DK3133396T3 publication Critical patent/DK3133396T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK16176456.8T 2008-08-29 2009-01-07 METHODS OF TREATMENT WHEN USING AMMONIA-CLEANING MEDICINES DK3133396T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9323408P 2008-08-29 2008-08-29
EP09739263.3A EP2330892B1 (en) 2008-04-29 2009-01-07 Methods of treatment using ammonia-scavenging drugs

Publications (1)

Publication Number Publication Date
DK3133396T3 true DK3133396T3 (en) 2018-12-03

Family

ID=45604478

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16176456.8T DK3133396T3 (en) 2008-08-29 2009-01-07 METHODS OF TREATMENT WHEN USING AMMONIA-CLEANING MEDICINES

Country Status (10)

Country Link
JP (3) JP5577341B2 (hr)
DK (1) DK3133396T3 (hr)
ES (2) ES2695534T3 (hr)
HR (2) HRP20161222T1 (hr)
HU (2) HUE029912T2 (hr)
LT (2) LT2330892T (hr)
PL (1) PL2330892T3 (hr)
PT (2) PT2330892T (hr)
SI (1) SI3133396T1 (hr)
TR (1) TR201816616T4 (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2760479T3 (en) 2011-09-30 2017-07-17 Horizon Therapeutics Llc Nitrogen-removing drug for use in a method of treating a nitrogen retention disorder
CN113995743A (zh) * 2012-04-20 2022-02-01 伊梅尔迪卡制药公司 苯乙酸前药的治疗性监测方法
US9289406B2 (en) * 2012-11-21 2016-03-22 Horizon Therapeutics, Inc. Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
JP6797456B2 (ja) * 2018-10-04 2020-12-09 アトナープ株式会社 生体情報取得システム、健康管理サーバーおよびシステム

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
ES2157422T3 (es) * 1995-02-07 2001-08-16 Brusilow Entpr Llc Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos.
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate

Also Published As

Publication number Publication date
LT3133396T (lt) 2018-11-26
LT2330892T (lt) 2016-11-25
ES2695534T3 (es) 2019-01-08
HUE029912T2 (en) 2017-03-28
JP5577341B2 (ja) 2014-08-20
PL2330892T3 (pl) 2017-05-31
JP2012501329A (ja) 2012-01-19
JP2014102255A (ja) 2014-06-05
ES2593378T3 (es) 2016-12-09
HRP20161222T1 (hr) 2017-02-10
HRP20181877T1 (hr) 2019-01-11
HUE040503T2 (hu) 2019-03-28
PT3133396T (pt) 2018-12-07
JP2012501451A (ja) 2012-01-19
SI3133396T1 (sl) 2018-12-31
PT2330892T (pt) 2016-09-05
TR201816616T4 (tr) 2018-11-21

Similar Documents

Publication Publication Date Title
DK2330892T3 (en) METHODS OF TREATMENT WITH USE OF AMMONIAK COLLECTIVE MEDICINES
US20120022157A1 (en) Dosing and monitoring patients on nitrogen-scavenging drugs
DK3133396T3 (en) METHODS OF TREATMENT WHEN USING AMMONIA-CLEANING MEDICINES
EP2846791B1 (en) Hpn-100 for use in the treatment of nitrogen retention disorders
EP2760479B1 (en) Nitrogen scavenging drug for use in a method of treating a nitrogen retention disorder
JP2013056918A (ja) グリシン捕捉性アンタゴニストを用いる拒絶性および認知性精神分裂病症候群の処置
WO2019110619A1 (en) Bis-choline tetrathiomolybdate for treating wilson disease
EP2986325B1 (en) Methods of treating urea cycle disorders
Zanchi et al. Endotheliai function of the mesenteric arteriole and mechanical behaviour of the carotid artery in rats with insulin resistance and hypercholesterolaemia
Karasawa et al. A cross-sectional multivariate analysis of the relationship between dental health and metabolic syndrome
WO2023230560A1 (en) Treatment of organic acidemias or pantothenate kinase associated neurodegeneration with modulators of pantothenate kinases